Tina Dutt
YOU?
Author Swipe
View article: Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial
Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial Open
Background: Atypical Haemolytic Uraemic Syndrome is a rare disease, associated with high morbidity and mortality. Eculizumab, a monoclonal complement inhibitor, is an effective treatment but the optimal way to use this high-cost medication…
View article: The Highs and Lows of ADAMTS13 Activity
The Highs and Lows of ADAMTS13 Activity Open
Severe deficiency of ADAMTS13 (<10 iu/dL) is diagnostic of thrombotic thrombocytopenic purpura (TTP) and leads to accumulation of ultra-large vWF multimers, platelet aggregation, and widespread microthrombi, which can be life-threatening. …
View article: Practical Considerations for the Use of the Rapid AcuStar® ADAMTS13 Activity Assay in the Diagnosis of Acute Thrombotic Thrombocytopenic Purpura (TTP)
Practical Considerations for the Use of the Rapid AcuStar® ADAMTS13 Activity Assay in the Diagnosis of Acute Thrombotic Thrombocytopenic Purpura (TTP) Open
Introduction: Conventional practice in the management of acute TTP entails empirical treatment of suspected cases whilst awaiting confirmatory ADAMTS13 deficiency testing. Rapid ADAMTS13 assays offer increased accessibility and rapid diagn…
View article: Caplacizumab in pediatric immune thrombotic thrombocytopenic purpura: the UK TTP Registry experience
Caplacizumab in pediatric immune thrombotic thrombocytopenic purpura: the UK TTP Registry experience Open
Pediatric thrombotic thrombocytopenic purpura (TTP) is an ultrarare disease. Immune TTP (iTTP) is driven by anti-ADAMTS13 autoantibodies causing an imbalanced von Willebrand factor (VWF):ADAMTS13 axis, and rarer still in children, but pote…
View article: The Highs and Lows of ADAMTS13 Activity
The Highs and Lows of ADAMTS13 Activity Open
Severe deficiency of ADAMTS13 (<10 iu/dL) is diagnostic of thrombotic thrombocytopenic purpura (TTP) and leads to accumulation of ultra-large VWF multimers, platelet aggregation and widespread microthrombi, which can be life-threatening…
View article: Real‐world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the <scp>TRAIT</scp> study
Real‐world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the <span>TRAIT</span> study Open
Summary Few studies have reported the real‐world use of both romiplostim and eltrombopag in immune thrombocytopenia (ITP). TRAIT was a retrospective observational study aimed to evaluate the platelet responses and adverse effects associate…
View article: Shades of Grey—The brain in <scp>TTP</scp>
Shades of Grey—The brain in <span>TTP</span> Open
In their paper, Hannan et al. suggest that new approaches to the management of the acute and remission phases of thrombotic thrombocytopenic purpura should be considered to address white matter changes seen in patients undergoing magnetic …
View article: A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies
A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies Open
Summary The objective of this guideline is to provide healthcare professionals with clear, up‐to‐date and practical guidance on the management of thrombotic thrombocytopenic purpura (TTP) and related thrombotic microangiopathies (TMAs), in…
View article: S305: PHASE 2 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER STUDY OF RECOMBINANT ADAMTS13 IN PATIENTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA
S305: PHASE 2 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER STUDY OF RECOMBINANT ADAMTS13 IN PATIENTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA Open
Topic: 32. Platelet disorders Background: Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare disorder caused by a severe ADAMTS13 deficiency, due to anti-ADAMTS13 autoantibodies. iTTP treatment includes plasma exchange (P…
View article: Integrating psychology services for patients with thrombotic thrombocytopenic purpura: A specialist centre experience
Integrating psychology services for patients with thrombotic thrombocytopenic purpura: A specialist centre experience Open
[Image: see text]
View article: Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study
Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study Open
Historically, the majority of patients with complement-mediated atypical hemolytic uremic syndrome (CaHUS) progress to end-stage kidney disease (ESKD). Single-arm trials of eculizumab with a short follow-up suggested efficacy. We prove, fo…
View article: Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy
Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy Open
Disease relapse is recognized as a risk in immune-mediated thrombotic thrombocytopenic purpura (iTTP) after treatment of the acute presenting episode. Identification of patients at risk of relapse and its patterns are yet to be clearly est…
View article: GWAS meta-analysis of intrahepatic cholestasis of pregnancy implicates multiple hepatic genes and regulatory elements
GWAS meta-analysis of intrahepatic cholestasis of pregnancy implicates multiple hepatic genes and regulatory elements Open
View article: Unmet needs in the management of immune‐mediated thrombotic thrombocytopenic purpura and the potential role of caplacizumab in the UK—A modified‐Delphi study
Unmet needs in the management of immune‐mediated thrombotic thrombocytopenic purpura and the potential role of caplacizumab in the UK—A modified‐Delphi study Open
Immune‐mediated thrombotic thrombocytopenic purpura (iTTP) is an ultra‐rare, blood‐clotting disorder. Management historically relies on plasma exchange and immunosuppression; however, a 10%–20% mortality rate is still observed. Caplacizuma…
View article: Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine: Comment from Doyle et al.
Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine: Comment from Doyle et al. Open
View article: Diagnostic uncertainty presented barriers to the timely management of acute thrombotic thrombocytopenic purpura in the United Kingdom between 2014 and 2019
Diagnostic uncertainty presented barriers to the timely management of acute thrombotic thrombocytopenic purpura in the United Kingdom between 2014 and 2019 Open
View article: Clinical outcomes and the impact of prior oral anticoagulant use in patients with coronavirus disease 2019 admitted to hospitals in the UK — a multicentre observational study
Clinical outcomes and the impact of prior oral anticoagulant use in patients with coronavirus disease 2019 admitted to hospitals in the UK — a multicentre observational study Open
Summary Coagulation dysfunction and thrombosis are major complications in patients with coronavirus disease 2019 (COVID‐19). Patients on oral anticoagulants (OAC) prior to diagnosis of COVID‐19 may therefore have better outcomes. In this m…
View article: The clinical course of COVID‐19 in pregnant <i>versus</i> non‐pregnant women requiring hospitalisation: results from the multicentre UK CA‐COVID‐19 study
The clinical course of COVID‐19 in pregnant <i>versus</i> non‐pregnant women requiring hospitalisation: results from the multicentre UK CA‐COVID‐19 study Open
Summary The impact of COVID‐19 infection on pregnant women remains relatively unknown but the physiological changes of pregnancy and hypercoagulability of COVID‐19 may further increase thrombotic risk. In this retrospective multicentre obs…
View article: Rectus sheath and retroperitoneal haematomas in patients with Coronavirus 2019 infection
Rectus sheath and retroperitoneal haematomas in patients with Coronavirus 2019 infection Open
High rates of venous thromboembolism (VTE) have been observed in Coronavirus 2019 disease (COVID-19).1 Regulatory bodies in the UK advise pharmacological VTE prophylaxis with standard prophylactic low-molecular-weight heparin (LMWH) dosing…
View article: Circulating histones play a central role in COVID-19-associated coagulopathy and mortality
Circulating histones play a central role in COVID-19-associated coagulopathy and mortality Open
Circulating histones play a central role in COVID-19-associated coagulopathy and mortality COVID-19 has highlighted the lethal consequences of immunothrombosis; i.e., the cross-talk between coagulation, inflammation and the innate immune s…
View article: POS-455 RITUXIMAB IN MANAGEMENT OF PEDIATRIC NEPHROTIC SYNDROME
POS-455 RITUXIMAB IN MANAGEMENT OF PEDIATRIC NEPHROTIC SYNDROME Open
Idiopathic nephrotic syndrome is the most common chronic glomerular disease in children. At least 20 % of children with this syndrome show frequent relapses and/or steroid dependence during or after immunosuppressive therapies, a condition…
View article: Clinical Outcomes and the Impact of Oral Anticoagulants Prior to Diagnosis of COVID-19 on Clinical Outcomes in Patients Admitted to Hospitals in the UK – a Multicentre Observational Study
Clinical Outcomes and the Impact of Oral Anticoagulants Prior to Diagnosis of COVID-19 on Clinical Outcomes in Patients Admitted to Hospitals in the UK – a Multicentre Observational Study Open
View article: Real-world experience with caplacizumab in the management of acute TTP
Real-world experience with caplacizumab in the management of acute TTP Open
The cornerstone of life-saving therapy in immune-mediated thrombotic thrombocytopenic purpura (iTTP) has been plasma exchange (PEX) combined with immunomodulatory strategies. Caplacizumab, a novel anti–von Willebrand factor nanobody triale…
View article: Circulating Histone Levels Correlate with the Severity of COVID-19 and the Extent of Coagulation Activation and Inflammation
Circulating Histone Levels Correlate with the Severity of COVID-19 and the Extent of Coagulation Activation and Inflammation Open
Background The COVID-19 pandemic has highlighted the potentially lethal consequences of cross-talk between coagulation, inflammation and innate immune processes. Hospitalised COVID-19 patients die of respiratory and multi-organ failure and…
View article: Reply to Rappaport <i>et al.</i>: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
Reply to Rappaport <i>et al.</i>: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19 Open
Dutt T, Simcox D, Downey C, McLenaghan, D, King, C, Gautam, M, Lane, S, Burhan, H, Thromboprophylaxis in COVID-19: Anti-FXa - The Missing Factor? [published online ahead of print, 2020 Jun 8]. Am J Respir Crit Care Med. 2020;10.1164/rccm.2…
View article: Thromboprophylaxis in COVID-19: Anti-FXa—the Missing Factor?
Thromboprophylaxis in COVID-19: Anti-FXa—the Missing Factor? Open
View article: Developing today’s trainees to become tomorrow’s clinical researchers – an innovative collaboration driving improvements in clinical training and research delivery
Developing today’s trainees to become tomorrow’s clinical researchers – an innovative collaboration driving improvements in clinical training and research delivery Open
To develop a unique partnership that enables specialty trainees to become regional champions in research, contributing to the ‘delivery of best research for best health’ while gaining essential clinical research skills for their future.
T…
View article: A simulation-based preceptorship for patients with rare and life-threatening illness: working together with a regional specialist treatment centre to improve patient outcomes nationally
A simulation-based preceptorship for patients with rare and life-threatening illness: working together with a regional specialist treatment centre to improve patient outcomes nationally Open
To deliver a unique 'simulation-based preceptorship' programme for NHS trusts managing patients with rare but life-threatening disease. Thrombotic microangiopathies (TMAs) are a group of rare conditions representing medical emergencies, wi…
View article: Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens
Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens Open
Key Points Rituximab is effective in preventing relapse in TTP patients in remission with low ADAMTS13 levels. Reduced-dose rituximab (200 mg) is associated with higher rates of re-treatment than the standard dose (375 mg/m2).
View article: Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura
Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura Open
Key Points High anti-ADAMTS13 antibody and low ADAMTS13 antigen levels adversely affect outcome in immune-mediated TTP with greater mortality seen. A raised troponin at presentation confers a sixfold increase and reduced GCS a nine-fold in…